BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision & Ophthalmology A...
April 16 2019 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company developing new cellular therapies, announced
today that updated results from a Phase I/IIa clinical study of its
lead product candidate, OpRegen®, a retinal pigment epithelium
(RPE) cell transplant therapy currently in development for the
treatment of dry age-related macular degeneration (AMD) with
geographic atrophy, will be presented at the 2019 Association for
Research in Vision and Ophthalmology Annual Meeting (ARVO 2019), to
be held April 28 through May 2, 2019 at the Vancouver Convention
Centre in Vancouver, BC, Canada.
The abstract presentation, entitled, “Phase I/IIa Clinical Trial
of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented
Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form
Age-Related Macular Degeneration (AMD): Interim Results,” will be
presented as part of the Advances in Retinal Gene Therapy and Stem
Cells Session on May 2, 2019 between 10:15 AM and 12:00
PM EDT in Session Number 530 by Eyal Banin, MD, PhD, Professor
of Ophthalmology, Director, Center for Retinal and Macular
Degenerations, Department of Ophthalmology at Hadassah-Hebrew
University Medical Center (presentation number 6402). The abstract
will provide updated data from patient cohorts 1 through 3 of the
study and new data from the ongoing patient cohort 4 in better
vision patients.
In addition, BioTime will present preclinical results from its
Vision Restoration Program, the Company’s proprietary research
program focused on developing technology that allows the generation
of three-dimensional human retinal tissue derived from human
pluripotent cells. BioTime’s three-dimensional retinal tissue
technology is being developed to potentially address a wide range
of severe retinal degenerative conditions (e.g. retinitis
pigmentosa and advanced forms of AMD) through a retinal tissue
restoration strategy. In 2017, the Small Business Innovation
Research program of the National Institutes of Health awarded
BioTime a grant of up to $1.56 million to further develop this
innovative, next generation vision restoration program.
- The poster presentation, entitled,
“Transplantation of human embryonic stem cell derived retinal
tissue in the subretinal space of immunodeficient rats with retinal
degeneration (RD),” will be presented as part of the Animal Models
for Visual Disease and Restoration Session on April 30, 2019
between 8:45am and 10:30am EDT in Session Number 332 by Igor
Nasonkin, PhD, Principal Investigator, Director of Research &
Development at BioTime, Inc. (Posterboard Number: 3109 -
A0500).
- The poster presentation, entitled,
“Evaluation of selected Human Embryonic Stem Cell Lines for
differentiation to three-dimensional retinal tissue (organoids) for
cell therapies of retinal degenerative conditions,” will be
presented as part of the Stem Cells and Retinal Organoids: Disease
Modeling Session on April 30, 2019 between 8:45am and
10:30am EDT in Session Number 323 by Ratnesh Singh, PhD,
Senior Scientist at BioTime, Inc. (Posterboard Number: 2873 -
A0044).
About OpRegen®
OpRegen is a retinal pigment epithelium transplant therapy in
Phase I/IIa development for the treatment of dry AMD, the leading
cause of adult blindness in the developed world. OpRegen consists
of a suspension of RPE cells delivered subretinally as an
intraocular injection. RPE cells are essential components of the
back lining of the retina and function to help nourish the retina
including photoreceptors. OpRegen has been granted Fast Track
designation from the U.S. Food and Drug
Administration.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company developing new
cellular therapies for degenerative retinal diseases, neurological
conditions associated with demyelination, and aiding the body in
detecting and combating cancer. BioTime’s programs are based on its
proprietary cell-based therapy platform and associated development
and manufacturing capabilities. With this platform BioTime develops
and manufactures specialized, terminally-differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed either to replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury, or administered as a means of helping the body
mount an effective immune response to cancer. BioTime’s clinical
assets include (i) OpRegen®, a retinal pigment epithelium
transplant therapy in Phase I/IIa development for the treatment of
dry age-related macular degeneration, the leading cause of
blindness in the developed world; (ii) OPC1, an oligodendrocyte
progenitor cell therapy in Phase I/IIa development for the
treatment of acute spinal cord injuries; and (iii) VAC2, an
allogeneic cancer immunotherapy of antigen-presenting dendritic
cells currently in Phase I development for the treatment of
non-small cell lung cancer. For more information, please visit
www.biotimeinc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190416005136/en/
BioTime Inc. IRIoana C. Hone(ir@biotimeinc.com)(510)
871-4188
Solebury Trout IRGitanjali Jain
Ogawa(Gogawa@troutgroup.com)(646) 378-2949
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024